Key points from article :
Immorta Bio, a Miami-based longevity biotechnology company, has published promising new results in the Journal of Stem Cell Research & Therapeutics showing that its personalized mesenchymal stem cells (pMSC) significantly outperform traditional stem cell sources in treating rheumatoid arthritis in preclinical studies. In a collagen-induced arthritis (CIA) animal model, intravenous injections of Immorta Bio’s proprietary pMSC reduced arthritis scores and swelling more effectively than standard bone marrow or umbilical cord-derived MSCs, suggesting superior immunomodulatory and regenerative benefits.
Led by Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, the research was a collaboration with BioCentrium, Loma Linda University, and the Azimi Cardiovascular Institute. Dr. Ichim emphasized that while mesenchymal stem cells have shown promise in thousands of clinical trials, their potential has been limited by challenges such as aging of a patient’s own cells and rejection of donor cells. Immorta Bio addresses this by using a novel approach to reprogram a patient’s own cells into “Personalized Regenerative Cells” (PRC), which are then converted into youthful pMSC for therapy.
These findings support the company’s broader mission to treat age-related diseases—and aging itself—through two core platforms: StemCell Revivify™, which delivers revitalized stem cells unique to each patient, and SenoVax™, a senolytic immunotherapy that targets harmful, aging-related senescent cells. The new data reinforce Immorta Bio’s approach, showing how its technologies may not only combat specific immune-related diseases like rheumatoid arthritis but also contribute to longer, healthier lifespans.
